Risk of ESRD in the United States

American Journal of Kidney Diseases

Volumn 68, Issue 6, 2016, Pages 862-872

  Albertus, Patrick ^a,b   Morgenstern, Hal ^b,c   Robinson, Bruce ^b,c,d   Saran, Rajiv ^a,b,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

Author keywords

cumulative incidence; End stage renal disease (ESRD); epidemiology; health inequity; incidence; lifetable; lifetime risk; mortality; nationwide surveillance; public health; racial disparity; risk; risk estimate; US Renal Data System (USRDS)

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; AMERICAN INDIAN; ARTICLE; ASIAN; BIRTH; BLACK PERSON; CAUCASIAN; CHILD; CONTROLLED STUDY; DEATH; END STAGE RENAL DISEASE; ETHNICITY; FEMALE; HISPANIC; HUMAN; INCIDENCE; INFANT; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; NEWBORN; PACIFIC ISLANDER; RACE; RISK FACTOR; SCHOOL CHILD; SEX; UNITED STATES; VERY ELDERLY; YOUNG ADULT; ANCESTRY GROUP; COMPARATIVE STUDY; KIDNEY FAILURE, CHRONIC; PRESCHOOL CHILD; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CONTINENTAL POPULATION GROUPS; FEMALE; HUMANS; INCIDENCE; INFANT; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

EID: 84994431070     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2016.05.030     Document Type: Article

References (36)

1. 1 Saran, R., Li, Y., Robinson, B., et al. US Renal Data System 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 66:1 suppl 1 (2015), S1–S306.
2. 2 Choi, A.I., Rodriguez, R.A., Bacchetti, P., Bertenthal, D., Hernandez, G.T., O'Hare, A.M., White/black racial differences in risk of end-stage renal disease and death. Am J Med 122:7 (2009), 672–678.
3. 3 Morgenstern, H., Kleinbaum, D.G., Kupper, L.L., Measures of disease incidence used in epidemiologic research. Int J Epidemiol 9:1 (1980), 97–104.
4. 4 Gail, M.H., Applications of personalized estimates of absolute breast cancer risk. Stat Biosci 5:2 (2013), 303–315.
5. 5 Merrill, R.M., Kessler, L.G., Udler, J.M., Rasband, G.C., Feuer, E.J., Comparison of risk estimates for selected diseases and causes of death. Prev Med 28:2 (1999), 179–193.
6. 6 Kiberd, B.A., Clase, C.M., Cumulative risk for developing end-stage renal disease in the US population. J Am Soc Nephrol 13:6 (2002), 1635–1644.
7. 7 Grams, M.E., Chow, E.K.H., Segev, D.L., Coresh, J., Lifetime incidence of CKD stages 3-5 in the United States. Am J Kidney Dis 62:2 (2013), 245–252.
8. 8 Turin, T.C., Tonelli, M., Manns, B.J., et al. Lifetime risk of ESRD. J Am Soc Nephrol 23:9 (2012), 1569–1578.
9. 9 Hoerger, T.J., Simpson, S.A., Yarnoff, B.O., et al. The future burden of CKD in the United States: a simulation model for the CDC CKD Initiative. Am J Kidney Dis 65:3 (2015), 403–411.
10. 10 Van Calster, B., Steyerberg, E.W., Harrell, F.H., Risk prediction for individuals. [editorial] JAMA, 314(17), 2015, 1875.
11. 11 Phillips, K.-A., Glendon, G., Knight, J.A., Putting the risk of breast cancer in perspective. [editorial] N Engl J Med 340:2 (1999), 141–144.
12. 12 Feuer, E.J., Wun, L.-M., Boring, C.C., Flanders, W.D., Timmel, M.J., Tong, T., The lifetime risk of developing breast cancer. J Natl Cancer Inst 85:11 (1993), 892–897.
13. 13 Vasan, R.S., Beiser, A., Seshadri, S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 287:8 (2002), 1003–1010.
14. 14 Narayan, K., Boyle, J.P., Thompson, T.J., Sorensen, S.W., Williamson, D.F., Lifetime risk for diabetes mellitus in the United States. JAMA 290:14 (2003), 1884–1890.
15. 15 Carone, M., Asgharian, M., Jewell, N.P., Estimating the lifetime risk of dementia in the Canadian elderly population using cross-sectional cohort survival data. J Am Stat Assoc 109:505 (2014), 24–35.
16. 16 Fay, M.P., Estimating age conditional probability of developing disease from surveillance data. Popul Health Metr, 2, 2004 http://dx.doi.org/10.1186/1478-7954-2-6.
17. 17 Fay, M.P., Pfeiffer, R., Cronin, K.A., Le, C., Feuer, E.J., Age-conditional probabilities of developing cancer. Stat Med 22:11 (2003), 1837–1848.
18. 18 DevCan. Probability of Developing or Dying of Cancer Software, Version 6.7.2 [Internet]. 2005. http://srab.cancer.gov/devcan/. Accessed October 15, 2015.
19. 19 Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying cause of death 1999-2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. http://wonder.cdc.gov/ucd-icd10.html. Accessed October 16, 2015.
20. 20 Wun, L.M., Merrill, R.M., Feuer, E.J., Estimating lifetime and age-conditional probabilities of developing cancer. Lifetime Data Anal 4:2 (1998), 169–186.
21. 21 Agodoa, L., Eggers, P., Racial and ethnic disparities in end-stage kidney failure - survival paradoxes in African-Americans. Semin Dial 20:6 (2007), 577–585.
22. 22 Klag, M.J., Whelton, P.K., Randall, B.L., Neaton, J.D., Brancati, F.L., Stamler, J., End-stage renal disease in African-American and white men - 16-year MRFIT findings. JAMA 277:16 (1997), 1293–1298.
23. 23 Tarver-Carr, M.E., Powe, N.R., Eberhardt, M.S., et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol 13:9 (2002), 2363–2370.
24. 24 Li, S.Y., McAlpine, D.D., Liu, J.N., Li, S.L., Collins, A.J., Differences between blacks and whites in the incidence of end-stage renal disease and associated risk factors. Adv Ren Replace Ther 11:1 (2004), 5–13.
25. 25 Peralta, C.A., Shlipak, M.G., Fan, D.J., et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol 17:10 (2006), 2892–2899.
26. 26 McClellan, W.M., Warnock, D.G., Judd, S., et al. Albuminuria and racial disparities in the risk for ESRD. J Am Soc Nephrol 22:9 (2011), 1721–1728.
27. 27 Foster, M.C., Coresh, J., Fornage, M., et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24:9 (2013), 1484–1491.
28. 28 Genovese, G., Friedman, D.J., Ross, M.D., et al. Association of trypanolytic APOL1 variants with kidney disease in African Americans. Science 329:5993 (2010), 841–845.
29. 29 Langefeld, C.D., Divers, J., Pajewski, N.M., et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int 87:1 (2015), 169–175.
30. 30 Parsa, A., Kao, W.H.L., Xie, D.W., et al. APOL1 Risk variants, race, and progression of chronic kidney disease. N Engl J Med 369:23 (2013), 2183–2196.
31. 31 Tzur, S., Rosset, S., Shemer, R., et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128:3 (2010), 345–350.
32. 32 Tayo, B.O., Kramer, H., Salako, B.L., et al. Genetic variation in APOL1 and MYH9 genes is associated with chronic kidney disease among Nigerians. Int Urol Nephrol 45:2 (2013), 485–494.
33. 33 Brophy, P.D., Shoham, D.A., Charlton, J.R., et al. Early-life course socioeconomic factors and chronic kidney disease. Adv Chronic Kidney Dis 22:1 (2015), 16–23.
34. 34 Wang, Y.J., Katzmarzyk, P.T., Horswell, R., et al. Racial disparities in diabetic complications in an underinsured population. J Clin Endocrinol Metab 97:12 (2012), 4446–4453.
35. 35 Bruce, M.A., Beech, B.M., Sims, M., et al. Social environmental stressors, psychological factors, and kidney disease. J Invest Med 57:4 (2009), 583–589.
36. 36 Bruce, M.A., Griffith, D.M., Thorpe, R.J., Stress and the kidney. Adv Chronic Kidney Dis 22:1 (2015), 46–53.